The uncontrolled growth of cancer cells is caused by their innate tendency to multiply without limits. In addition to colonizing adjacent tissues, they are capable of forming aggregates in isolated anatomical sites, thereby significantly increasing their invasiveness. Over time, malignant tumors that progressively destroy essential tissues and organs are ultimately lethal. It is well known that growth factor-driven signaling influence malignancy. The transmembrane receptor tyrosine kinases of growth factors influence the survival, differentiation, and proliferation of cells. To expedite cell division, neurotransmitters and proteins resembling epidermal growth factor (EGF) stimulate EGF receptor (EGFR) family members including HER2-4 and EGFR. The development and growth of numerous varieties of human cancer cells, as well as the morphogenesis of numerous animal species (nematodes to humans), are influenced by this signaling module, which is remarkably conserved. The EGFR family, consisting of over thirty ligands and four receptors, forms a complex and advanced human signal transduction network. The T790M mutation in the EGFR kinase enhances treatment resistance by increasing the affinity for ATP. This work used a molecular design tool to evaluate quinazoline derivatives with the highest IC50 values against EGFR and analyze the molecular interactions in the binding site. The goal was to uncover novel compounds with promising potential.
Adottu DD, Shajahan AM, Koolaparambil SA, Rasheed SP, Vengamthodi A, Pattilthodika S, Rasheed A. Investigating the activity of Quinazoline derivatives against T790 mutant EGFR receptors employing computer-aided drug design. J Appl Pharm Sci. 2024. Online First. http://doi.org/10.7324/JAPS.2024.188300
1. Silverman RB. The organic chemistry of drug design and drug action, power PDF. Amsterdam, The Netherlands: Elsevier; 2005 Feb 4. | |
2. Gomaa HA. A comprehensive review of recent advances in the biological activities of quinazolines. Chem Biol Drug Design. 2022 Nov; 100(5):639-55. https://doi.org/10.1111/cbdd.14129 | |
3. Mishra S. Quinazolinone and quinazoline derivatives: synthesis and biological application. Quinazolinone and quinazoline derivatives. IntechOpen. 2020 May 6;10:75-90. https://doi.org/10.5772/intechopen.89203 | |
4. Mattiuzzi C, Lippi G. Cancer statistics: a comparison between world health organization (WHO) and global burden of disease (GBD). Eur J Public Health. 2020 Oct; 30(5):1026-7. https://doi.org/10.1093/eurpub/ckz216 | |
5. Patergnani S, Danese A, Bouhamida E, Aguiari G, Previati M, Pinton P, et al. Various aspects of calcium signaling in the regulation of apoptosis, autophagy, cell proliferation, and cancer. Int J Mol Sci. 2020 Nov 6;21(21):8323. https://doi.org/10.3390/ijms21218323 | |
6. Shin I. HER2 Signaling in breast cancer. In translational research in breast cancer. Singapore: Springer Singapore; 2021. pp 53-79. https://doi.org/10.1007/978-981-32-9620-6_3 | |
7. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):S21-6. https://doi.org/10.1016/j.ijrobp.2003.11.041 | |
8. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006 Jan 17;366(1):2-16. https://doi.org/10.1016/j.gene.2005.10.018 | |
9. Kim M, Baek M, Kim DJ. Protein tyrosine signaling and its potential therapeutic implications in carcinogenesis. Curr Pharm Design. 2017 Aug 1;23(29):4226-46. https://doi.org/10.2174/1381612823666170616082125 | |
10. Gao X, Le X, Costa DB. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016 Apr 2;16(4):383-90. https://doi.org/10.1586/14737140.2016.1162103 | |
11. Ko B, Paucar D, Halmos B. EGFR T790M: revealing the secrets of a gatekeeper. Lung Cancer: Targets Ther. 2017 Oct 9:147-59. https://doi.org/10.2147/LCTT.S117944 | |
12. Khrustalev VV, Khrustaleva TA, Poboinev VV, Yurchenko KV. Mutational pressure and natural selection in epidermal growth factor receptor gene during germline and somatic mutagenesis in cancer cells. Mutat Res. 2019 May 1;815:1-9. https://doi.org/10.1016/j.mrfmmm.2019.03.001 | |
13. Kang JJ, Ko A, Kil SH, Clair JM, Shin DS, Wang MB, et al. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochim Biophys Acta Rev Cancer. 2023 Jan 1;1878(1):188827. https://doi.org/10.1016/j.bbcan.2022.188827 | |
14. Thangaraj K, Arumugasamy K, Natesan K, Ramasamy S, Cyril R, Singh SK, et al. In Silico molecular docking analysis of Orientin, a potent glycoside of luteolin against BCL-2 family proteins. J. Chem. Pharm. Res. 2017;9:65-72. | |
15. Mohammed AH, Gomaa RM, El-Sayed MA, Selim KB. Synthesis, antitumor activities, and molecular modeling of 4-anilinoquinazoline derivatives as EGFR-TK inhibitors. Pharm Chem J. 2024;6:1-5. https://doi.org/10.1007/s11094-024-03029-w | |
16. Zayed MF. Medicinal chemistry of quinazolines as anticancer agents targeting tyrosine kinases. Sci Pharm. 2023 Mar 28;91(2):18. https://doi.org/10.3390/scipharm91020018 | |
17. Zhang Y, Zhang Y, Liu J, Chen L, Zhao L, Li B, et al. Synthesis and in vitro biological evaluation of novel quinazoline derivatives. Bioorg Med Chem Lett. 2017 Apr 1;27(7):1584-7. https://doi.org/10.1016/j.bmcl.2017.02.027 | |
18. Hisham M, Hassan HA, Gomaa HA, Youssif BG, Hayallah AM, Abdel-Aziz M. Structure-based design, synthesis and antiproliferative action of new quinazoline-4-one/chalcone hybrids as EGFR inhibitors. J Mol Struct. 2022 Apr 15;1254:132422. https://doi.org/10.1016/j.molstruc.2022.132422 | |
19. Allam HA, Ibrahim BT, El-Dydamony NM, Fouad MA, Mohammed ER. Exploring new quinazolin-4 (3H)-one derivatives as CDK2 inhibitors: design, synthesis, and anticancer evaluation. Drug Dev Res. 2024 Apr;85(2):e22163. https://doi.org/10.1002/ddr.22163 | |
20. Kaur J, Kaur S, Anand A, Islam N, Singh S, Singh A. An updated overview on the synthesis and anticancer evaluation of quinazoline derivatives. ChemistrySelect. 2023 Aug 11;8(30):e202302778. https://doi.org/10.1002/slct.202302778 | |
21. Bansal R, Malhotra A. Therapeutic progression of quinazolines as targeted chemotherapeutic agents. Eur J Med Chem. 2021 Feb 5;211:113016. https://doi.org/10.1016/j.ejmech.2020.113016 | |
22. Abd El Hadi SR, Lasheen DS, Soliman DH, Elrazaz EZ, Abouzid KA. Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors. Bioorg Chem. 2020 Aug 1;101:103961. https://doi.org/10.1016/j.bioorg.2020.103961 | |
23. Kaur G, Cholia RP, Joshi G, Amrutkar SM, Kalra S, Mantha AK, et al. Anticancer activity of dihydropyrazolo [1, 5-c] quinazolines against rat C6 glioma cells via inhibition of topoisomerase II. Archiv der Pharmazie. 2018 Jun; 351(6):1800023. https://doi.org/10.1002/ardp.201800023 | |
24. Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers. 2021 Jun 1;13(11):2748. https://doi.org/10.3390/cancers13112748 | |
25. Kumagai S, Koyama S, Nishikawa H. Antitumour immunity regulated by aberrant ERBB family signalling. Nature Rev Cancer. 2021 Mar; 21(3):181-97. https://doi.org/10.1038/s41568-020-00322-0 | |
26. Singh D, Attri BK, Gill RK, Bariwal J. Review on EGFR inhibitors: critical updates. Mini Rev Med Chem. 2016 Sep 1;16(14):1134-66. https://doi.org/10.2174/1389557516666160321114917 | |
Year
Month